TOX3 Biomarker Detection and Modulation in Breast Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for breast cancer treatment are limited in understanding and targeting the molecular mechanisms underlying the disease, particularly the role of the TOX3 gene in breast cancer development and progression, which is associated with increased susceptibility and estrogen receptor-positive tumors.
Innovation Solution
Development of modulators, such as antisense molecules, antibodies, and small molecules, targeting the TOX3 gene to detect and modulate its expression and activity, along with the use of transgenic mice models to study its role in breast cancer, providing tools for potential therapeutic interventions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If current breast cancer treatment methods are used, then treatment can be provided, but understanding and targeting the molecular mechanisms underlying the disease is limited
Solution Approach 1:
The patent applies preliminary action by identifying and characterizing TOX3 as a biomarker before developing treatments. Microarray analysis was performed to detect TOX3 expression patterns in breast cancer cells, establishing a molecular understanding that precedes and guides therapeutic intervention. This allows treatment strategies to be designed based on pre-established molecular mechanisms rather than empirical approaches.
2Adaptability or versatility
If TOX3-targeted modulators are developed, then new therapeutic strategies can be provided, but the complexity of the treatment approach increases
Solution Approach 1:
The patent uses TOX3 as an intermediary biomarker that mediates between the complex molecular mechanisms of breast cancer and clinically applicable treatments. By targeting TOX3 expression and activity, the invention creates a simplified interface that translates complex genomic data into actionable therapeutic targets, reducing the effective complexity of the treatment approach while maintaining adaptability.
3Measurement precision
If TOX3 expression is used as a biomarker, then breast cancer susceptibility can be detected, but the precision of detection methods must be validated
Solution Approach 1:
The patent implements feedback by using microarray analysis to detect TOX3 expression levels and comparing these against known breast cancer susceptibility data. The method incorporates validation through comparison with established biomarkers and clinical outcomes, creating a feedback loop that refines detection precision while maintaining reliability through iterative verification.
Data Source
AI summary
The invention provides compositions and methods for detecting and/or modulating TOX3 gene expression and/or biological activity. Such compositions and methods find utility in the detection and/or treatment of certain subsets of cancers, e.g. breast cancer. In particular, the inventive compositions and methods are drawn to production and use of anti-TOX3 antibodies and TOX3 nucleic acids for both detection and modulation of TOX3. The invention also provides for pharmaceutical compositions and methods for the modulation of TOX3 in a subject in need thereof. Further aspects of the invention relate to transgenic mice that either over-express or inducibly express TOX3.